Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment.
latent tuberculosis infection
long-acting
tuberculosis
tuberculosis preventive treatment
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
21 11 2022
21 11 2022
Historique:
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
24
11
2022
Statut:
ppublish
Résumé
A key component of global tuberculosis (TB) control is the treatment of latent TB infection. The use of long-acting technologies to administer TB preventive treatment has the potential to significantly improve the delivery and impact of this important public health intervention. For example, an ideal long-acting treatment could consist of a single dose that could be administered in the clinic (ie, a "1-shot cure" for latent TB). Interest in long-acting formulations for TB preventive therapy has gained considerable traction in recent years. This article presents an overview of the specific considerations and current preclinical advancements relevant for the development of long-acting technologies of TB drugs for treatment of latent infection, including attributes of target product profiles, suitability of drugs for long-acting formulations, ongoing research efforts, and translation to clinical studies.
Identifiants
pubmed: 36410384
pii: 6835720
doi: 10.1093/cid/ciac672
pmc: PMC10200320
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S510-S516Subventions
Organisme : NIAID NIH HHS
ID : R61 AI161809
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Potential conflicts of interest. N.C.A. reports research funding from Johns Hopkins University, Janssen, Unitaid, and NIH grants R61AI161809 and 1P30AI094189 and receipt of research materials from Janssen. E.N. reports research funding from Johns Hopkins University, Unitaid, NIH, Janssen, and TB Alliance. He also reports payments for participating in a Janssen advisory board. C.F.M. reports research funding from Unitaid and NIH grant R01 Al134091 and a likely planned patent on INH prodrugs for LA. A.O. is a Director of Tandem Nano Ltd, and co-inventor of several patents relating to drug delivery. A.O. has received research funding from ViiV Healthcare, Merck, Janssen, GSK, Tandem Nano Ltd., and Gilead. He also reports receiving consulting fees from Gilead, ViiV Healthcare, Merck, and Tandem Nano Ltd. S.P.R. reports research funding from Unitaid and report patents related to long-acting therapeutic inventions through the University of Liverpool and is the vice-chair of the nonprofit British Society for Nanomedicine. S.S. reports research funding to her institution from ViiV Healthcare, Unitaid, and NIH grant NIAID R24 AI118397. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Innov Clin Neurosci. 2015 May-Jun;12(5-6):10-1
pubmed: 26155371
Lancet Infect Dis. 2016 Nov;16(11):1269-1278
pubmed: 27522233
Int J Tuberc Lung Dis. 2018 Aug 1;22(8):937-944
pubmed: 29991405
Clin Infect Dis. 2015 Oct 15;61(8):1322-7
pubmed: 26082504
Emerg Infect Dis. 2006 May;12(5):744-51
pubmed: 16704830
Curr Opin HIV AIDS. 2017 Jul;12(4):355-358
pubmed: 28403028
Int J Nanomedicine. 2018 Jul 23;13:4303-4318
pubmed: 30087562
Int J Tuberc Lung Dis. 2016 Aug;20(8):1065-71
pubmed: 27393541
Microbiol Spectr. 2017 Jun;5(3):
pubmed: 28643624
Am J Respir Crit Care Med. 2022 Mar 1;205(5):570-579
pubmed: 34939891
N Engl J Med. 2011 Dec 8;365(23):2155-66
pubmed: 22150035
Lancet HIV. 2020 Jun;7(6):e401-e409
pubmed: 32240629
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0170521
pubmed: 34606336
Int J Tuberc Lung Dis. 2022 Apr 1;26(4):302-309
pubmed: 35351234
Small. 2015 Oct;11(38):5066-78
pubmed: 26193431
Clin Infect Dis. 2015 Oct 15;61(8):1328-35
pubmed: 26105170
Antimicrob Agents Chemother. 2019 Mar 27;63(4):
pubmed: 30745396
FASEB J. 2014 Dec;28(12):5071-82
pubmed: 25122556
N Engl J Med. 2019 Mar 14;380(11):1001-1011
pubmed: 30865794
Clin Infect Dis. 2013 Aug;57(4):586-93
pubmed: 23592830
J Infect. 2020 Dec;81(6):873-881
pubmed: 33007340
J Antimicrob Chemother. 2014 Apr;69(4):1079-85
pubmed: 24343893
Biomacromolecules. 2021 Sep 13;22(9):3756-3768
pubmed: 34339606
Ann Am Thorac Soc. 2020 Apr;17(4):438-449
pubmed: 31860328
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:495-516
pubmed: 32806997
Int J Tuberc Lung Dis. 2018 Feb 1;22(2):125-132
pubmed: 29506608
Clin Infect Dis. 2020 Feb 3;70(4):549-556
pubmed: 30918967